- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute
- Interventions
- aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500
- Drug · Biological · Device
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Condition Directory
Myelodysplastic Syndromes clinical trials
Directory of U.S. ClinicalTrials.gov public records for Myelodysplastic Syndromes. Browse Myelodysplastic Syndromes recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 16, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1797
Shown on this page
12
Local recruiting
73
Local phase groups
5
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Myelodysplastic Syndromes studies are organized in the registry
MDS listings rely on risk-stratum vocabulary — “lower-risk” and “higher-risk MDS” describe different study populations and appear in titles. The portfolio overlaps with AML research, and some records list both conditions because higher-risk MDS studies often allow or track progression to AML.
- 63% of the 116 locally indexed Myelodysplastic Syndromes records are currently marked recruiting.
- The most common phase group in the local index is Phase 1 (50 records).
- The most frequent sponsor is Dana-Farber Cancer Institute (7 records).
- The most listed study location is Houston, Texas (31 records).
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 1–12 of 1,797 matching trials for Myelodysplastic Syndromes.
Live ClinicalTrials.gov results.
Phase distribution
Phase 1 50
Phase 2 47
Not applicable 13
Phase 3 7
Early Phase 1 3
Top locations
Top sponsors
Top therapies
Live official records
Open in full search- Conditions
- Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- Interventions
- AUTX-703
- Drug
- Lead sponsor
- Auron Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Duarte, California • Tampa, Florida • Buffalo, New York + 6 more
- Conditions
- VEXAS, VEXAS Syndrome
- Interventions
- Pacritinib, Placebo
- Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Rochester, Minnesota + 6 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Interventions
- Not listed
- Lead sponsor
- CareDx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 10
- States / cities
- Brisbane, California • Duarte, California • Tampa, Florida + 7 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Day to 120 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2042
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML
- Interventions
- AlloHeme
- Diagnostic Test
- Lead sponsor
- CareDx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Brisbane, California • San Francisco, California • St Louis, Missouri
- Conditions
- Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
- Interventions
- LLS Program
- Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Miami, Florida • Chicago, Illinois • San Antonio, Texas
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS), Non-Hodgkins Lymphoma, Acute Myelogenous Leukemia, Hodgkins Lymphoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 120 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2052
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Germline Mutation, Myelodysplastic Syndromes, Acute Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Month to 120 Years
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease, Mucosal Ulcerations
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 99 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2056
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
- Interventions
- Biopsy
- Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Months and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 16
- States / cities
- Sacramento, California • Aurora, Colorado • Atlanta, Georgia + 13 more
About this Myelodysplastic Syndromes clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Myelodysplastic Syndromes as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Myelodysplastic Syndromes.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Myelodysplastic Syndromes.